PhysIQ Wins DPharm IDOL 2017
PhysIQ, a Chicago-based leader in developing solutions that leverage artificial intelligence (AI) to empower digital health for ambulatory patient monitoring and clinical trial support, was named DPharm Idol 2017 at the 7th annual DPharm: Disruptive Innovations to Advance Clinical Trials Conference. Amid tough competition, PhysIQ’s VP Business Development had only six minutes to pitch the company’s contribution to disrupting the future of clinical trials. The conference was held earlier this month in Boston Massachusetts.
Recently, the Global Health Sciences (GHS) Fund through Quark Venture and GF Securities announced a $2 million investment in PhysIQ.
“We are pleased to see PhysIQ’s game-changing product being recognized at the DPharm, a conference that focuses on innovations, new models and collaborations to advance clinical trials,” said Karimah Es Sabar.
Go here for more information about PhysIQ’s recognition.
